| 产品描述： | STAT5-IN-1 是一种有效的选择性 STAT5 抑制剂，其对于STAT5β亚型的IC50值为47 μM |
| 靶点： |
STAT5β(Cell-free assay):47 μM;STAT |
| 体外研究： |
STAT5-IN-1, the STAT5 phosphorylation specific inhibitor, selectively blocks the STAT5 signaling and decreases the percentage of CD4+CD25+Foxp3+ Tregs after SEC2 stimulation on murine splenocytes |
| 体内研究： |
STAT5-IN-1, a STAT5 inhibitor, significantly attenuates atherosclerosis in ApoE-/- mice induced by HFD via decreasing inflammation. |
| 细胞实验： |
Cell lines: murine splenocytes Concentrations: 0.47 mM Incubation Time: 3 days Method: Fresh murine splenocytes seeded in 24-well flat-bottom plates are treated with each inhibitor at final concentrations of 10 μM LY294002, 10 mM Trigonelline, 0.47 mM STAT5-IN-1, 50 μM SB431542, and 1 μM SIS3, or treated with 10 μg/mL anti-IL-2 neutralizing antibody, respectively, then cells are stimulated with 104 ng/mL SEC2 for 3 days in a humidified incubator at 37 ℃ with 5% CO2. |
| 动物实验： |
Animal Models: ApoE-/- mice Dosages: 10 mg/kg Administration: p.o. |
| 参考文献： |
1. Müller J, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008 Mar 25;9(5):723-7. 2. Li Y, et al. Induction of CD4+ regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways. Biomed Pharmacother. 2021 Nov;143:112204. 3. Wang X, et al. STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis. Am J Transl Res. 2021;13(3):1422-1431. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.41 ml |
17.049 ml |
34.097 ml |
| 5 mM |
0.682 ml |
3.41 ml |
6.819 ml |
| 10 mM |
0.341 ml |
1.705 ml |
3.41 ml |
| 50 mM |
0.068 ml |
0.341 ml |
0.682 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京